Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine and Rituximab Following SRS in CNS Lymphomas
NCT06607549Phase 1Recruiting
- Sponsor
- University of Utah
- Start
- Mar 2025
- Primary completion
- Nov 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loncastuximab tesirine in central nervous system lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by University of Utah. Primary endpoint: Maximum Tolerated Dose / Safe and Tolerable Dose at 5 years. Started Mar 2025; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
central nervous system lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06607549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607549.